HIV-associated Burkitt lymphoma: Outcomes from a US-UK collaborative analysis

Juan Pablo Alderuccio, Adam J. Olszewski, Andrew M. Evens, Graham P. Collins, Alexey V. Danilov, Mark Bower, Deepa Jagadeesh, Catherine Zhu, Amy Sperling, Seo Hyun Kim, Ryan Vaca, Catherine Wei, Suchitra Sundaram, Nishitha Reddy, Alessia Dalla Pria, Christopher D'Angelo, Umar Farooq, David A. Bond, Stephanie Berg, Michael C. ChurnetskiAmandeep Godara, Nadia Khan, Yun Kyong Choi, Shireen Kassam, Maryam Yazdy, Emma Rabinovich, Frank A. Post, Gaurav Varma, Reem Karmali, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas Klein, Kristie A. Blum, Kirsten Marie Boughan, Agrima Mian, Bradley M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Seth M. Maliske, Narendranath Epperla, Paolo Caimi, Scott E. Smith, Manali Kamdar, Parameswaran Venugopal, Tatyana A. Feldman, Daniel Rector, Stephen D. Smith, Andrzej Stadnik, Craig A. Portell, Yong Lin, Seema Naik, Silvia Montoto, Izidore S. Lossos, Kate Cwynarski

Research output: Contribution to journalArticlepeer-review

Abstract

Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) patients with HIV-BL treated from 2008 to 2019 aiming to identify prognostic factors and outcomes. With a median follow up of 4.5 years, the 3- year progression-free survival (PFS) and overall survival (OS) were 61% (95% confidence interval [CI] 55% to 67%) and 66% (95%CI 59% to 71%), respectively, with similar results in both countries. Patients with baseline central nervous system (CNS) involvement had shorter 3-year PFS (36%) compared to patients without CNS involvement (69%; P < .001) independent of frontline treatment. The incidence of CNS recurrence at 3 years across all treatments was 11% with a higher incidence observed after dose-adjusted infusional etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide (DA-EPOCH) (subdistribution hazard ratio: 2.52; P = .03 vs other regimens) without difference by CD4 count 100/mm3. In multivariate models, factors independently associated with inferior PFS were Eastern Cooperative Oncology Group (ECOG) performance status 2-4 (hazard ratio [HR] 1.87; P = .007), baseline CNS involvement (HR 1.70; P = .023), lactate dehydrogenase >5 upper limit of normal (HR 2.09; P < .001); and >1 extranodal sites (HR 1.58; P = .043). The same variables were significant in multivariate models for OS. Adjusting for these prognostic factors, treatment with cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate, ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) was associated with longer PFS (adjusted HR [aHR] 0.45; P = .005) and OS (aHR 0.44; P = .007). Remarkably, HIV features no longer influence prognosis in contemporaneously treated HIV-BL.

Original languageEnglish (US)
Pages (from-to)2852-2862
Number of pages11
JournalBlood Advances
Volume5
Issue number14
DOIs
StatePublished - Jul 27 2021

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'HIV-associated Burkitt lymphoma: Outcomes from a US-UK collaborative analysis'. Together they form a unique fingerprint.

Cite this